LONDON, Sept. 13, 2016 /PRNewswire/ -- Next-generation antibody therapeutics refer to the improved antibody therapeutics with enhanced efficiency, greater safety, and improved delivery. Next-generation antibody-based therapeutics overcome the limitations of monoclonal antibodies and feature enhancements to existing properties of therapeutic antibodies. Various biotechnology and biopharmaceutical companies are actively involved in development of next-generation antibody therapeutics, especially for cancer, autoimmune, and inflammatory diseases. Factors such as growing R&D activities, increasing prevalence of chronic diseases, technological advancements in antibody therapeutics, and rising healthcare expenditure are driving growth of the global next-generation antibody therapeutics market. However, stringent regulatory requirements, long approval times for new drugs, and high costs of next-generation antibody therapeutics are some of the key restraints for growth of the market.
North America is the largest market for next-generation antibody therapeutics. The U.S. represents the largest market for next-generation antibody therapeutics in the region. This is due to the increasing prevalence of chronic diseases, rising healthcare expenditure, and growing R&D activities in the country.
This report provides in-depth analysis and estimation of the global next-generation antibody therapeutics market for the period 2015–2022, considering 2014 as the base year for calculations. In addition, data pertaining to current market dynamics, including market drivers, restraints, and strategic developments has been provided in the report. The next-generation antibody therapeutics market is categorized on the basis of technology, therapeutic application, and geography. Based on technology, the next-generation antibody therapeutics market is segmented into antibody-drug conjugates (ADCs), bispecific antibodies (BsAbs), Fc engineered antibodies, antibody fragments and antibody-like proteins, and biosimilar antibody products. In terms of therapeutic application, the market is segmented into oncology and autoimmune/inflammatory diseases. In the geographical analysis, the report identifies and analyzes market size and forecast for North America, Europe, Asia, and Rest of the World (RoW).
Some of the major players in the market are F. Hoffmann-La Roche Ltd., Kyowa Hakko Kirin Co., Ltd., Seattle Genetics, Inc. ImmunoGen, Inc., Amgen, Inc., Biogen, Bayer AG, and Xencor, Inc. These key market players have been profiled on the basis of attributes such as company overview, recent developments, growth strategies, sustainability and financial overview.
Download the full report: https://www.reportbuyer.com/product/3306974/
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers
For more information:
Research Advisor at Reportbuyer.com
Tel: +44 208 816 85 48
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-market-study-on-next-generation-antibody-therapeutics-biosimilar-antibody-products-to-witness-highest-growth-by-2022-300327623.html